30-01-2020 дата публикации
Номер: US20200031819A1
Принадлежит:
The present invention provides compounds for the prevention or treatment of cancer or a bacterial or viral infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the prevention or treatment of cancer or a bacterial or viral infection in a subject. 116-. (canceled)18Pseudomonas aeruginosa, Chlamydia trachomatis, Escherichia coli, Helicobacter pylori, Listeria monocytogenes, Salmonella typhimurium, Shigella flexneriMycobacterium tuberculosis.. The method of claim 17 , wherein the mammal is suffering from a bacterial infection caused by claim 17 , or19. The method of claim 17 , wherein the mammal is suffering from a viral infection caused by a Vaccinia virus claim 17 , a variola virus claim 17 , a polyoma virus claim 17 , a Pox virus claim 17 , a Herpes virus claim 17 , a cytomegalovirus claim 17 , a human immunodeficiency virus claim 17 , JC virus claim 17 , JC polyomavirus claim 17 , BK polyomavirus claim 17 , Simian virus 40 claim 17 , Monkeypox virus claim 17 , Ebola virus claim 17 , Marburg virus claim 17 , Bunyavirus claim 17 , Arenavirus claim 17 , Alphavirus claim 17 , Flavivirus claim 17 , West Nile virus or Coronavirus.20. The method of claim 19 , wherein the mammal is suffering from a lytic infection of JC virus in the brain.21. The method of claim 17 , wherein the compound is a methanesulfonic acid salt.22. The method of claim 17 , wherein the compound is a succinic acid salt.23. The method of claim 17 , wherein the compound is a free base. This application is a continuation of U.S. patent application Ser. No. 16/169,683, now issued as U.S. Pat. No. 10,344,027, filed Oct. 24, 2019, which is a continuation of U.S. patent application Ser. No. 15/805,693, now issued as U.S. Pat. No. 10,118,923, filed Nov. 7, 2017, which is a continuation of U.S. patent application Ser. No. 15/136,497, now issued as U.S. Pat. No. 9,828,370, filed Apr. 22, 2016, which claims the benefit of, and priority to, ...
Подробнее